---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-067485"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:45:44.987253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Iovance reports $363M cash, 50+ ATCs onboard for Amtagvi; frontline melanoma data shows 65.2% ORR

## Summary
- Cash position of ~$363M as of 3/31/2024; 600+ employees and 50+ payers covering 200M+ lives have approved Amtagvi for at least one patient.
- 50 Authorized Treatment Centers onboarded by 5/28/2024; targeting ~70 by end of 2024; 100+ patients enrolled by 5/9/2024.
- EU submission for Amtagvi planned in 2Q2024; UK and Canada submissions in 2H2024.
- Phase 2 frontline melanoma (IOV-COM-202 Cohort 1A) results: ORR 65.2%, CR 30.4%, median PFS not reached at 21.7 months follow-up.
- Registrational TILVANCE-301 Phase 3 trial for frontline melanoma randomized first patient in 2Q2023; dual primary endpoints ORR and PFS.

## SEC filing metadata
- accession: 0001104659-24-067485
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924067485/0001104659-24-067485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924067485/tm2416237d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-067485
- JSON: https://secwatch.observer/filing/0001104659-24-067485.json
- Plain text: https://secwatch.observer/filing/0001104659-24-067485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.